J Med Life Sci > Volume 9(1); 2012 > Article
Journal of Medicine and Life Science 2012;9(1):16-22.
DOI: https://doi.org/10.22730/jmls.2012.9.1.16    Published online June 30, 2012.
라미부딘 치료로 HBeAg 혈청전환 후 재발한 만성B형간염 환자에서 유전자의 변이
최수길, 조유경, 송병철
제주대학교 의학전문대학원 내과학교실
Genetic change of full-length hepatitis B virus in relapsed patients with chronic hepatitis B after lamivudine-induced HBeAg seroconversion
Xiu Ji Cui, Yoo-Kyung Cho, Byung-Cheol Song
Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea
Correspondence:  Byung-Cheol Song, Email: drsong@jejunu.ac.kr
Abstract
Even though, therapy-induced HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection is durable in Western patients, frequent relapse of HBV has been reported in Korea. ln addition, HBV genotype C, which is prevalent in Korea, has been reported to be associated with relapse after lamivudine-induced HBeAg seroconversion, suggesting some viral factor might be associated with relapse after lamivudine-induced HBeAg seroconversion. Therefore. the goal of this study is to analyze the genetic changes of full-Iength HBV in relapsed 6 patients with chronic hepatitis B after lamivudine-induced HBeAg seroconversion. Full-length HBV DNA sequences at baseline. at the time of HBeAg seroconversion and relapse were analyzed. Amino acid substitutions and nucleotide changes occurred in specific regions in core protein, X protein, reverse transcriptase and basal core promoter (BCP). In the core protein. cP130T, cY88G, cE18oG were frequently detected. In X protein, xK130M, xV131F were found in all six patients at any time points. ln amino acids in reverse transcriptase, rtK267Q was observed in 4 patients. Mutations in the BCP occurred in all patients at baseline. At the time of HBeAg seroconversion, BCP mutation observed in 3 patients. However. at relapse, BCP mutation observed in 4 patients. ln patients with relapse after lamivudine-induced HBeAg seroconversion, substitution in specific amino acid and preexisting BCP mutation might contribute to the high relapse in Korean patient with chronic hepatitis B.
Key Words: chronic hepatitis B; Iamivudine; HBeAg seroconversion; relpase


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
102, Jejudaehak-ro, Jeju-si, Jeju-do 63243, Republic of Korea
Tel: +82-64-754-8023    E-mail: jmls.jeju@gmail.com                

Copyright © 2024 by Jeju National University Institute for Medical Science.

Developed in M2PI

Close layer
prev next